Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (111-120 of 238) with videos related to

Pageof 24
Sort By:
European Journal of Clinical Pharmacology|March 16, 2012
Entry-into-humans study with a new direct renin inhibitorLaurent B Nicolas, Marcelo M Gutierrez, Christoph Binkert, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 7, 2020
Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313Priska Kaufmann, Marion Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology|February 19, 2020
First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonistPriska Kaufmann, Marion Ort, Georg Golor, et al.
Journal of Clinical Pharmacology|July 24, 2009
Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|October 2, 2007
Influence of ethnic origin and sex on the pharmacokinetics of clazosentanPaul L M van Giersbergen, Kulasiri A Gunawardena, Jasper Dingemanse
Clinical and Experimental Pharmacology & Physiology|July 1, 2020
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatinIsabelle Zenklusen, Clemens Muehlan, Ivan Ulc, et al.
Journal of Clinical Pharmacology|August 1, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|April 3, 2014
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexantMatthias Hoch, Helene van Gorsel, Joop van Gerven, et al.
European Journal of Clinical Pharmacology|September 20, 2012
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Journal of Clinical Psychopharmacology|March 6, 2020
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian SubjectsClemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Pageof 24

Showing results (111-120 of 238) with videos related to

Sort By:
Pageof 24
European Journal of Clinical Pharmacology|March 16, 2012
Entry-into-humans study with a new direct renin inhibitorLaurent B Nicolas, Marcelo M Gutierrez, Christoph Binkert, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 7, 2020
Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313Priska Kaufmann, Marion Ort, Georg Golor, et al.
British Journal of Clinical Pharmacology|February 19, 2020
First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonistPriska Kaufmann, Marion Ort, Georg Golor, et al.
Journal of Clinical Pharmacology|July 24, 2009
Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|October 2, 2007
Influence of ethnic origin and sex on the pharmacokinetics of clazosentanPaul L M van Giersbergen, Kulasiri A Gunawardena, Jasper Dingemanse
Clinical and Experimental Pharmacology & Physiology|July 1, 2020
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatinIsabelle Zenklusen, Clemens Muehlan, Ivan Ulc, et al.
Journal of Clinical Pharmacology|August 1, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|April 3, 2014
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexantMatthias Hoch, Helene van Gorsel, Joop van Gerven, et al.
European Journal of Clinical Pharmacology|September 20, 2012
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Journal of Clinical Psychopharmacology|March 6, 2020
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian SubjectsClemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Pageof 24